NYSE:MNK Mallinckrodt Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mallinckrodt plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.33 -0.03 (-8.33 %) (As of 03/5/2021 12:00 AM ET) Add Compare Share Today's Range$0.30Now: $0.33▼$0.3650-Day Range$0.14MA: $0.34▼$0.7552-Week Range$0.75Now: $0.33▼$6.42Volume687,491 shsAverage Volume6.49 million shsMarket Capitalization$27.91 millionP/E RatioN/ADividend YieldN/ABeta3.06 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.Read More HeadlinesEndo Aims to Rework $3.3 Billion Loan as Opioid Litigation Looms - BloombergMarch 4, 2021 | bloomberg.comOpioid claimants look to probe Mallinckrodt's pre-bankruptcy activityFebruary 26, 2021 | reuters.comOpioid claimants look to probe Mallinckrodt's pre-bankruptcy activity - ReutersFebruary 26, 2021 | reuters.comMallinckrodt judge OKs Kenneth Feinberg to mediate opioid trust disputes - ReutersFebruary 12, 2021 | reuters.comMallinckrodt (MNKKQ) Stock Sinks As Market Gains: What You Should Know - Yahoo FinanceFebruary 11, 2021 | finance.yahoo.comThe Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment - BenzingaFebruary 2, 2021 | benzinga.comMallinckrodt Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality IndexJanuary 29, 2021 | prnewswire.comMallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease - Yahoo FinanceJanuary 28, 2021 | finance.yahoo.comMallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host DiseaseJanuary 28, 2021 | finance.yahoo.comThe Buxton Helmsley Group Announces Sufficient Shareholder Backing to Call Mallinckrodt Meeting of Shareholders, Begin Realigning Board and Management with Shareholder Interests, Renegotiate Restructuring Plan - PRNewswireJanuary 27, 2021 | prnewswire.comObituary: George Mallinckrodt, banker, 1930-2021 - Financial TimesJanuary 22, 2021 | ft.comThe Buxton Helmsley Group to Call Meeting of Mallinckrodt Shareholders to Realign Board and Management with Shareholder Interests, Renegotiate Restructuring Plan - PRNewswireJanuary 16, 2021 | prnewswire.comeFFECTOR Appoints Mike Byrnes as Chief Financial Officer - StreetInsider.comJanuary 8, 2021 | streetinsider.comWhy St. Louis company stocks remained negative for the year, while national stocks boomed - St. Louis Business JournalJanuary 7, 2021 | bizjournals.comSilence Therapeutics Appoints Craig Tooman as Chief Financial Officer - StreetInsider.comJanuary 6, 2021 | streetinsider.comSilence Therapeutics to Participate in January Virtual U.S. Investor Conferences - Yahoo FinanceJanuary 5, 2021 | finance.yahoo.comEndo Launches Authorized Generic Version of Amitiza® (lubiprostone) Capsules in the United States - PRNewswireJanuary 4, 2021 | prnewswire.comMallinckrodt bankruptcy judge rejects shareholders' bid for seat at the table - ReutersDecember 24, 2020 | reuters.comPro Bankruptcy Briefing: Sacklers Were Warned About Purdue's Risks; Shareholders Excluded From Mallinckrodt Talks; McKinsey Resolves Disclosure Spat - The Wall Street JournalDecember 23, 2020 | wsj.comShareholders Denied Official Seat at Mallinckrodt's Bankruptcy Bargaining Table - The Wall Street JournalDecember 22, 2020 | wsj.comSee More Headlines Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:MNK Previous Symbol CUSIPN/A CIK1567892 Webwww.mallinckrodt.com Phone(531) 696-0000Employees3,400Year FoundedN/ADebt Debt-to-Equity Ratio5.39 Current Ratio1.48 Quick Ratio1.23 Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio0.05 P/E Growth0.01 Sales & Book Value Annual Sales$3.16 billion Price / Sales0.01 Cash Flow$6.60 per share Price / Cash Flow0.05 Book Value$23.08 per share Price / Book0.01Profitability EPS (Most Recent Fiscal Year)$8.88 Net Income$-996,500,000.00 Net Margins-89.94% Return on Equity34.26% Return on Assets6.66% Miscellaneous Outstanding Shares84,589,000Market Cap$27.91 million Next Earnings DateN/A OptionableOptionable MarketRank™Overall MarketRank™1.72 out of 5 starsMedical Sector214th out of 1,969 stocksPharmaceutical Preparations Industry96th out of 771 stocksAnalyst Opinion: 2.8Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 - 2.8 Analyst's Opinion Consensus RatingMallinckrodt has received a consensus rating of Hold. The company's average rating score is 1.63, and is based on no buy ratings, 5 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.63, Mallinckrodt has a forecasted upside of 695.5% from its current price of $0.33.Amount of Analyst CoverageMallinckrodt has received no research coverage in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesMallinckrodt has received 987 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMallinckrodt has received 627 “underperform” votes. (Add your “underperform” vote.)Community SentimentMallinckrodt has received 61.15% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote “Outperform” if you believe MNK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMallinckrodt does not currently pay a dividend.Dividend GrowthMallinckrodt does not have a long track record of dividend growth. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mallinckrodt insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.14% of the stock of Mallinckrodt is held by insiders.Percentage Held by Institutions61.67% of the stock of Mallinckrodt is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Mallinckrodt are expected to decrease by -35.92% in the coming year, from $6.32 to $4.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mallinckrodt is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mallinckrodt is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioMallinckrodt has a PEG Ratio of 0.01. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioMallinckrodt has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Receive MNK News and Ratings via Email Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter. Mallinckrodt (NYSE:MNK) Frequently Asked Questions Is Mallinckrodt a buy right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last twelve months. There are currently 3 sell ratings and 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Mallinckrodt stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MNK, but not buy additional shares or sell existing shares. View analyst ratings for Mallinckrodt or view top-rated stocks. What stocks does MarketBeat like better than Mallinckrodt? Wall Street analysts have given Mallinckrodt a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Mallinckrodt wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How were Mallinckrodt's earnings last quarter? Mallinckrodt plc (NYSE:MNK) released its earnings results on Tuesday, August, 4th. The company reported $1.89 earnings per share for the quarter, topping analysts' consensus estimates of $1.34 by $0.55. The company had revenue of $700.90 million for the quarter, compared to analyst estimates of $630.19 million. Mallinckrodt had a positive trailing twelve-month return on equity of 34.26% and a negative net margin of 89.94%. The firm's revenue was down 14.9% compared to the same quarter last year. During the same quarter last year, the firm earned $2.53 EPS. View Mallinckrodt's earnings history. What price target have analysts set for MNK? 8 equities research analysts have issued 1-year price objectives for Mallinckrodt's stock. Their forecasts range from $1.50 to $4.00. On average, they expect Mallinckrodt's stock price to reach $2.63 in the next twelve months. This suggests a possible upside of 695.5% from the stock's current price. View analysts' price targets for Mallinckrodt or view top-rated stocks among Wall Street analysts. Who are Mallinckrodt's key executives? Mallinckrodt's management team includes the following people: Mark C. Trudeau, President, Chief Executive Officer & DirectorBryan M. Reasons, Chief Financial Officer & Executive Vice PresidentSteven Joseph Romano, Chief Scientific Officer & Executive VPBabatunde Adekunle Otulana, Chief Medical Officer & Senior Vice PresidentMichele Robertson, Chief Compliance Officer & Senior Vice President Who are some of Mallinckrodt's key competitors? Some companies that are related to Mallinckrodt include Oncolytics Biotech (ONCY), American BriVision (Holding) (ABVC), Capricor Therapeutics (CAPR), Marker Therapeutics (MRKR), Lumos Pharma (LUMO), Xynomic Pharmaceuticals (XYNO), Actinium Pharmaceuticals (ATNM), PhaseBio Pharmaceuticals (PHAS), NervGen Pharma (NGENF), Aravive (ARAV), BetterLife Pharma (PVOTF), ProPhase Labs (PRPH), Ocuphire Pharma (OCUP), Moleculin Biotech (MBRX) and Avenue Therapeutics (ATXI). View all of MNK's competitors. What other stocks do shareholders of Mallinckrodt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), (CELG) and Advanced Micro Devices (AMD). What is Mallinckrodt's stock symbol? Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK." Who are Mallinckrodt's major shareholders? Mallinckrodt's stock is owned by a variety of retail and institutional investors. Top institutional investors include KBC Group NV (1.34%) and Accredited Investors Inc. (0.36%). Company insiders that own Mallinckrodt stock include Bryan M Reasons and Mark Trudeau. View institutional ownership trends for Mallinckrodt. Which institutional investors are buying Mallinckrodt stock? MNK stock was purchased by a variety of institutional investors in the last quarter, including KBC Group NV, and Accredited Investors Inc.. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons, and Mark Trudeau. View insider buying and selling activity for Mallinckrodt or or view top insider-buying stocks. What is Mallinckrodt's stock price today? One share of MNK stock can currently be purchased for approximately $0.33. How much money does Mallinckrodt make? Mallinckrodt has a market capitalization of $27.91 million and generates $3.16 billion in revenue each year. The company earns $-996,500,000.00 in net income (profit) each year or $8.88 on an earnings per share basis. How many employees does Mallinckrodt have? Mallinckrodt employs 3,400 workers across the globe. What is Mallinckrodt's official website? The official website for Mallinckrodt is www.mallinckrodt.com. Where are Mallinckrodt's headquarters? Mallinckrodt is headquartered at COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. How can I contact Mallinckrodt? Mallinckrodt's mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The company can be reached via phone at (531) 696-0000 or via email at [email protected] This page was last updated on 3/7/2021 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here
